Kite Pharma, Changing the Way Cancer is Treated
WEBSingular Focus of Cell Therapy. CAR T-cell therapy is a custom-made, one-time cancer treatment that is designed to work by engineering a patient’s own white blood cells and harnessing their immune system to treat certain kinds of …
Kite Pharma - Wikipedia
WEBKite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead …
Careers at Kite - Kite Pharma
WEBEveryone at Kite is grounded by one common goal – curing cancer. Our personalized approach is what sets us apart from other health and life science companies. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. With CAR T-cell therapy, we are reengineering a patient’s own immune cells to fight ...
Our Focus on Cell Therapy | Kite Pharma
WEBA Singular Focus on Cell Therapy. Founded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016.
Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
WEBJan 30, 2024 · The FDA has approved a new manufacturing process change for Yescarta, Gilead’s Kite Pharma unit said Tuesday. The approval allows the company to shorten the CAR-T cell manufacturing time for ...
Gilead Sciences to Acquire Kite Pharma for 119 Billion
WEBAug 28, 2017 · Gilead Sciences to Acquire Kite Pharma for $11.9 Billion. -- Immediately Positions Gilead as a Leader in Cell Therapy --. -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU --. -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust …
Kite Joint Venture Fosun Kite Gains the First CAR T cell Therapy ...
WEBJun 23, 2021 · Axicabtagene Ciloleucel, FKC876, is an autologous CD19-directed CAR T-cell therapy manufactured in China under a license to YESCARTA® (Axicabtagene Ciloleucel) from Kite. The approval is based on results of a single-arm, open label, multi-center bridging trial (FKC876-2018-001) which has evaluated the efficacy and safety of …
Kite Receives U.S. FDA Approval of Manufacturing Process Change ...
WEBJan 30, 2024 · SANTA MONICA, Calif., January 30, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change ...
Kite’s next-gen CAR-T aims include quicker production
WEBFeb 20, 2024 · To date, Kite has treated more than 19,500 patients with its CAR-T therapies. The goal now is not only speed but broadened access. Currently, only 2 in 10 American patients who could benefit from CAR-T get the treatment, Perettie said. “This is a potentially curative therapy for almost half of the patients.
Cell Therapy Technology | Kite Pharma
WEBEnd-to-End Manufacturing for Kite CAR T-cell Therapies. CAR T-cell therapy is an individualized, one-time treatment that is changing the way cancer is treated. Our technology uses the power of a patient’s own immune system to attack certain types of cancer cells. At Kite, the cell therapy manufacturing process is personal, from initial ...